




Get Full Access and More at

ExpertConsult.com




Christopher D.M. Fletcher



DIAGNOSTIC HISTOPATHOLOGY OF TUMORS

Fourth Edition



Volume 1

ELSEVIER
SAUNDERS

DIAGNOSTIC HISTOPATHOLOGY OF TUMORS

Fourth Edition/Volume 1

Christopher D.M. Fletcher, MD, FRCPath

Vice Chair, Anatomic Pathology
Brigham and Women's Hospital
Chief of Onco-Pathology
Dana-Farber Cancer Institute
Professor of Pathology
Harvard Medical School
Boston, Massachusetts



ELSEVIER
SAUNDERS

ELSEVIER
SAUNDERS

1600 John F. Kennedy Blvd.
Ste. 100
Philadelphia, PA 19103-2899

DIAGNOSTIC HISTOPATHOLOGY OF TUMORS
FOURTH EDITION

Volume 1 PN 9996090442
Volume 2 PN 9996090388
Two-volume set ISBN: 978-1-4377-1534-7

Copyright © 2013 by Saunders, an imprint of Elsevier Inc.
Copyright © 2007, 2000, 1995, by Elsevier Limited, an imprint of Elsevier Inc.

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies, and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

With respect to any drug or pharmaceutical products identified, readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of practitioners, relying on their own experience and knowledge of their patients, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Library of Congress Cataloging-in-Publication Data

Diagnostic histopathology of tumors / [edited by] Christopher D.M. Fletcher.—4th ed.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-4377-1534-7 (2 v. set : alk. paper)

I. Fletcher, Christopher D.M.

[DNLM: 1. Neoplasms—pathology. QZ 241]

616.994075—dc23

2012041834

Executive Content Strategist: William R. Schmitt
Content Development Specialist: Kathryn DeFrancesco
Publishing Services Manager: Anne Altepetter
Project Manager: Louise King
Designer: Steven Stave

Printed in China

Last digit is the print number: 9 8 7 6 5 4 3 2

Working together to grow
libraries in developing countries

www.elsevier.com | www.bookaid.org | www.sabre.org

ELSEVIER

BOOK AID
International

Sabre Foundation

DIAGNOSTIC HISTOPATHOLOGY OF TUMORS

CONTRIBUTORS

Mahul B. Amin, MD

Professor and Chairman, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California
Tumors and Tumor-like Conditions of the Male Genital Tract

Alberto G. Ayala, MD

Deputy Chief of Pathology, Department of Pathology and Genomic Medicine, The Methodist Hospital; Professor of Pathology, Weill Medical College of Cornell University, Houston, Texas
Tumors and Tumor-like Conditions of the Male Genital Tract

J. Eduardo Calonje, MD, DipRCPath

Director of Dermatopathology, St. John's Institute of Dermatology, St. Thomas Hospital, London, United Kingdom
Vascular Tumors

Fiona Campbell, BSc, MD, FRCPath

Honorary Professor of Pathology, University of Liverpool; Consultant Gastrointestinal Pathologist, Department of Pathology, Royal Liverpool University Hospital, Liverpool, United Kingdom
Tumors of the Esophagus and Stomach

John K.C. Chan, MD

Consultant Pathologist, Department of Pathology, Queen Elizabeth Hospital, Hong Kong, China
Tumors of the Salivary Glands; Tumors of the Thyroid and Parathyroid Glands; Tumors of the Lymphoreticular System, Including Spleen and Thymus

Wah Cheuk, MD

Consultant Pathologist, Department of Pathology, Queen Elizabeth Hospital, Hong Kong, China
Tumors of the Salivary Glands

Philip B. Clement, MD

Professor Emeritus, Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia; Consultant Pathologist, Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, British Columbia, Canada
Tumors of the Peritoneum

Christopher P. Crum, MD

Professor of Pathology, Harvard Medical School; Director, Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts
Tumors of the Female Genital Tract (Part C: Tumors of the Placenta and Gestational Trophoblastic Disease, Part E: Cervix)

John N. Eble, MD, FRCA

Nordschow Professor of Laboratory Medicine, Chairman, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana
Tumors of the Urinary Tract

Ian O. Ellis, BM, BS, FRCPath

Professor of Cancer Pathology, Molecular Medical Sciences, University of Nottingham, Nottingham, United Kingdom
Tumors of the Breast

Linda Ferrell, MD

Professor, Vice Chairperson, and Director of Surgical Pathology, Department of Pathology, University of California, San Francisco, San Francisco, California
Tumors of the Liver, Biliary Tree, and Gallbladder

Christopher D.M. Fletcher, MD, FRCPath

Vice Chair, Anatomic Pathology, Brigham and Women's Hospital; Chief of Onco-Pathology, Dana-Farber Cancer Institute; Professor of Pathology, Harvard Medical School, Boston, Massachusetts
Introduction; Vascular Tumors; Tumors of Soft Tissue; Peripheral Neuroectodermal Tumors

Jonathan A. Fletcher, MD

Associate Professor of Pathology, Associate Professor of Pediatrics, Harvard Medical School; Director, Solid Tumor Cytogenetics, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts
Molecular Genetic Techniques in Diagnosis and Prognosis

Robert Folberg, MD

Founding Dean, Oakland University William Beaumont School of Medicine, Rochester, Michigan; Chief Academic Officer, Beaumont Health System, Royal Oak, Michigan
Tumors of the Eye and Ocular Adnexa

Karuna Garg, MBBS

Assistant Professor, Department of Pathology,
University of California, San Francisco,
San Francisco, California
*Tumors of the Female Genital Tract (Part A: Ovary,
Fallopian Tube, and Broad and Round Ligaments)*

David J. Grignon, MD, FRCP(C)

Centennial Professor and Vice Chair for Clinical
Programs, Department of Pathology, Indiana
University School of Medicine, Indianapolis, Indiana
Tumors of the Urinary Tract

Philipp U. Heitz, MD

Emeritus Professor of Pathology, Chairman Emeritus,
Department of Pathology, University of Zurich,
Zurich, Switzerland
Tumors of the Endocrine Pancreas

Jason L. Hornick, MD, PhD

Director of Surgical Pathology, Director,
Immunohistochemistry Laboratory, Brigham and
Women's Hospital; Associate Professor of Pathology,
Harvard Medical School, Boston, Massachusetts
*Tumors of the Small and Large Intestines, Including Anal
Canal*

Carrie Y. Inwards, MD

Associate Professor of Pathology, Mayo Clinic College
of Medicine; Department of Laboratory Medicine
and Pathology, Mayo Clinic, Rochester, Minnesota
Tumors of the Osteoarticular System

Julie A. Irving, MD

Clinical Associate Professor, Department of Pathology
and Laboratory Medicine, Faculty of Medicine,
University of British Columbia; Department of
Laboratory Medicine, Pathology, and Medical
Genetics, Royal Jubilee Hospital, Victoria, British
Columbia, Canada
Tumors of the Peritoneum

Sanjay Kakar, MD

Professor, Department of Anatomic Pathology,
University of California, San Francisco; Chief of
Pathology, Department of Anatomic Pathology,
Veterans Affairs Medical Center, San Francisco,
California
Tumors of the Liver, Biliary Tree, and Gallbladder

Kyu-Rae Kim, MD, PhD

Professor, Department of Pathology, Asan Medical
Center, University of Ulsan College of Medicine,
Seoul, Korea
*Tumors and Tumor-like Conditions of the Male Genital
Tract*

David S. Klimstra, MD

James Ewing Alumni Chair of Pathology, Department
of Pathology, Memorial Sloan-Kettering Cancer
Center, New York, New York
Tumors of the Exocrine Pancreas

Gunter Klöppel, MD

Professor Emeritus, Department of Pathology,
Technical University of Munich, Munich, Germany
*Tumors of the Exocrine Pancreas; Tumors of the
Endocrine Pancreas*

Jeffery L. Kutok, MD, PhD

Senior Director, Molecular Pathology, Infinity
Pharmaceuticals, Inc., Cambridge, Massachusetts
Tumors of the Hematopoietic System

Ernest E. Lack, MD

Senior Pathologist, Endocrine and Otorhinolaryngic-
Head and Neck Pathology, Joint Pathology Center,
Silver Spring, Maryland
*Tumors of the Adrenal Gland; Tumors of the Autonomic
Nervous System, Including Paraganglia*

Gregory Y. Lauwers, MD

Professor of Pathology, Harvard Medical School; Vice
Chairman, Department of Pathology, Massachusetts
General Hospital, Boston, Massachusetts
Tumors of the Esophagus and Stomach

Andrew H.S. Lee, MD, MRCP, FRCPath

Consultant Histopathologist, Nottingham University
Hospitals, City Hospital Campus, Nottingham,
United Kingdom
Tumors of the Breast

Kenneth R. Lee, MD

Associate Professor, Department of Pathology, Harvard
Medical School; Staff Pathologist, Department of
Pathology, Brigham and Women's Hospital, Boston,
Massachusetts
Tumors of the Female Genital Tract (Part E: Cervix)

Yonghee Lee, MD

Professor of Pathology, Department of Pathology, Ajou
University School of Medicine, Suwon, Korea
*Tumors of the Female Genital Tract (Part C: Tumors of
the Placenta and Gestational Trophoblastic Disease)*

Neal I. Lindeman, MD

Director of Molecular Diagnostics, Brigham and
Women's Hospital; Associate Professor of Pathology,
Harvard Medical School, Boston, Massachusetts
Molecular Genetic Techniques in Diagnosis and Prognosis

Janina A. Longtine, MD

Vice Chairperson, Molecular Pathology and Genetics,
Department of Pathology, The Mount Sinai Medical
Center, New York, New York
Molecular Genetic Techniques in Diagnosis and Prognosis

M. Beatriz S. Lopes, MD, PhD

Director of Neuropathology, Professor of Pathology
and Neurological Surgery, Department of Pathology,
Division of Neuropathology, University of Virginia
Health System, Charlottesville, Virginia
*Tumors of the Pituitary Gland; Tumors of the Central
Nervous System*

Joseph J. Maleszewski, MD

Assistant Professor of Pathology, Mayo Clinic College of Medicine; Senior Associate Consultant Pathologist, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
Tumors of the Heart and Pericardium

Cesar A. Moran, MD

Professor of Pathology, Section Chief, Thoracic Pathology, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Tumors of the Lung and Pleura

George L. Mutter, MD

Professor of Pathology, Department of Pathology, Harvard Medical School; Pathologist, Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts
Tumors of the Female Genital Tract (Part B: Endometrial Tumors)

Marisa R. Nucci, MD

Associate Professor of Pathology, Harvard Medical School; Associate Pathologist, Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts
Tumors of the Female Genital Tract (Part D: Myometrium, Part E: Cervix, Part F: Vagina, Part G: Vulva)

André M. Oliveira, MD, PhD

Associate Professor of Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
Tumors of the Osteoarticular System

Mana M. Parast, MD, PhD

Assistant Professor of Pathology, Department of Pathology, University of California, San Diego, La Jolla, California
Tumors of the Female Genital Tract (Part C: Tumors of the Placenta and Gestational Trophoblastic Disease)

Aurel Perren, MD

Professor of Pathology, Institute of Pathology, University of Bern, Bern, Switzerland
Tumors of the Endocrine Pancreas

Sarah E. Pinder, MD

Professor of Breast Pathology, Department of Cancer Studies, Research Oncology, King's College London; Consultant Breast Pathologist, Department of Histopathology, Guy's and St. Thomas Hospitals, London, United Kingdom
Tumors of the Breast

Emad A. Rakha, MD

Department of Cellular Pathology, University of Nottingham and Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, United Kingdom
Tumors of the Breast

Jae Y. Ro, MD, PhD

Director of Surgical Pathology, Department of Pathology and Genomic Medicine, The Methodist Hospital; Professor of Pathology, Weill Medical College of Cornell University; Adjunct Professor of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Tumors and Tumor-like Conditions of the Male Genital Tract

Scott Rodig, MD, PhD

Associate Professor, Department of Pathology, Harvard Medical School; Associate Pathologist, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts
Tumors of the Lymphoreticular System (Part A: Lymph Node; Part B: Spleen)

Daniel J. Santa Cruz, MD

Dermatopathologist, Cutaneous Pathology, WCP Laboratories, Inc., St. Louis, Missouri
Tumors of the Skin

Steven S. Shen, MD, PhD

Associate Director of Surgical Pathology, Department of Pathology and Genomic Medicine, The Methodist Hospital; Associate Professor of Pathology, Weill Medical College of Cornell University, Houston, Texas
Tumors and Tumor-like Conditions of the Male Genital Tract

Paul M. Speight, BDS, PhD, FRSRCPS, FRCPath

Dean and Professor in Oral Pathology, School of Clinical Dentistry, University of Sheffield, Sheffield, United Kingdom
Tumors of the Oral Cavity

Saul Suster, MD

Professor and Chairman, Department of Pathology and Laboratory Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
Tumors of the Lung and Pleura

Henry D. Tazelaar, MD

Professor of Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; Chairperson, Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, Arizona
Tumors of the Heart and Pericardium

Lester D.R. Thompson, MD

Consultant Pathologist, Department of Pathology, Southern California Permanente Medical Group, Woodland Hills, California
Tumors of the Ear

Scott R. VandenBerg, MD, PhD

Professor, Department of Pathology, Division of Neuropathology, University of California, San Diego; Director of Neuropathology, Department of Pathology, University of California, San Diego Medical Center, La Jolla, California
Tumors of the Central Nervous System

Sarah N. Walsh, MD

Dermatopathologist, Cutaneous Pathology, WCP Laboratories, Inc., St. Louis, Missouri
Tumors of the Skin

Bruce M. Wenig, MD

Chairman, Department of Diagnostic Pathology and Laboratory Medicine, Beth Israel Medical Center, St. Luke's and Roosevelt Hospitals, New York, New York; Professor of Pathology, Albert Einstein College of Medicine, Bronx, New York; Adjunct Professor of Pathology, Columbia University College of Medicine, New York, New York
Tumors of the Upper Respiratory Tract

Jacqueline Wieneke, MD

Medical Officer, Pathologist, U.S. Food and Drug Administration, Silver Spring, Maryland
Tumors of the Adrenal Gland; Tumors of the Autonomic Nervous System, Including Paraganglia

Robert H. Young, MD, FRCPath

Robert E. Scully Professor of Pathology, Department of Pathology, Harvard Medical School; Pathologist, James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Boston, Massachusetts
Tumors of the Urinary Tract

Charles J. Zaloudek, MD

Professor, Department of Pathology, University of California, San Francisco, San Francisco, California
Tumors of the Female Genital Tract (Part A: Ovary, Fallopian Tube, and Broad and Round Ligaments)

PREFACE

In the five-year interval since publication of *Diagnostic Histopathology of Tumors, Third Edition*, conventional morphologic and immunohistochemical assessment has continued to hold sway as the pre-eminent, most reliable, and most cost-effective means to provide a diagnosis, prognostic assessment, and in most cases, determination of the adequacy of excision for human tumors. Such interpretation also helps to guide therapy in many settings. The continued utility of such “traditional” technologies and interpretive skills is somewhat reassuring in the setting of the ever-widening disparities in the availability of more expensive modern technologies, such as molecular genetic diagnosis, gene expression profiling, and genomics, not only (to a depressing degree) between the developed and still developing (or underdeveloped) areas of the world, but even among different developed countries or regions.

The role of molecular diagnosis is now very well established and firmly integrated in the practice of modern surgical pathology, and is especially valuable in confirming the presence of diagnostically important gene fusions or mutations, in helping with therapeutic target identification and, not least, in enhancing diagnostic reproducibility and tumor classification schemes. Whereas some targets can be identified immunohistochemically, mutational analysis may better enable treatment selection in some contexts, especially in the setting of treatment resistance. A more complex issue, however, in some of the developed countries (with dangerously expanding health care expenditure) is the interface between pathology and genomic medicine. Expression profiling as well as whole genome sequencing are increasingly being promulgated as providing additional information of critical clinical importance—yet, at this point in time, the value of such testing has only rarely been demonstrated and validated, for example in prognostication for invasive carcinoma of the breast (Oncotype Dx and Mammprint assays)—while most other such testing remains unvalidated, analytically or clinically, and of unproven clinical value. In particular, there are no good data confirming that identification of a potentially targetable mutation in a tumor type in which the role of that specific gene has never been demonstrated represents anything more than a sophisticated (and expensive) shot in the dark. Similarly, gene expression profiling as a means of identifying the primary site

in metastatic carcinomas is rarely more effective than high-quality immunohistochemistry combined with morphologic expertise, is more expensive and, in any event, does not very often lead to clinically significant change in treatment or outcome (as many of the more treatable metastases are easily recognized by conventional means). It is troubling that many such commercial tests are being marketed directly to clinicians and patients, who are often completely unable to distinguish snake oil from clinically worthwhile testing. Although it is likely that genomic data will ultimately prove their (progressively more affordable) value, until then pathologists have a responsibility to ensure (a) that often limited patient tissue is used judiciously, and (b) that, in the routine (non-trial) setting, testing of any kind has proven clinical value that might merit action by the treating physician.

Remarkably, and seemingly with no evident slowing of the pace, morphologic tumor classifications and methods of prognostication continue to evolve and be ever more refined, constantly enhancing the value of high-quality anatomic pathology. Many of these advances have been codified in the new WHO classifications, which are currently being updated in a fourth edition of the “blue books.” Furthermore, “new” (newly recognized) tumor types or subtypes of clinical or therapeutic relevance continue to be characterized, both morphologically and genetically, in a seemingly limitless fashion. The fourth edition of this text has been substantially revised and updated to incorporate this broad range of new information. Some chapters have been entirely rewritten, notably those dealing with tumors of the small and large intestines, the heart, and the ear.

As always, any and all errors or omissions are entirely the responsibility of the editor, and I remain deeply indebted to the contributors for the unfailingly high quality of the material that they provide, as well as the enthusiasm with which they do so. Finally, I should like to warmly acknowledge, with considerable gratitude, the hard work and unfailing support of my outstanding secretary, Kathleen Radzikowski, and also of the “key players” at Elsevier—Bill Schmitt, Katie DeFrancesco, and Louise King.

Christopher D.M. Fletcher
Boston, 2012

CONTENTS

Volume 1

1. INTRODUCTION 1
Christopher D.M. Fletcher
2. TUMORS OF THE HEART AND PERICARDIUM 6
Henry D. Tazelaar, Joseph J. Maleszewski
3. VASCULAR TUMORS 42
J. Eduardo Calonje, Christopher D.M. Fletcher
4. TUMORS OF THE UPPER RESPIRATORY TRACT 92
PART A ■ NASAL CAVITY, PARANASAL SINUSES, AND NASOPHARYNX 92
Bruce M. Wenig
PART B ■ LARYNX, HYPOPHARYNX, AND TRACHEA 162
Bruce M. Wenig
5. TUMORS OF THE LUNG AND PLEURA 207
Saul Suster, Cesar A. Moran
6. TUMORS OF THE ORAL CAVITY 246
Paul M. Speight
7. TUMORS OF THE SALIVARY GLANDS 270
John K.C. Chan, Wah Cheuk
8. TUMORS OF THE ESOPHAGUS AND STOMACH 378
Fiona Campbell, Gregory Y. Lauwers
9. TUMORS OF THE SMALL AND LARGE INTESTINES, INCLUDING ANAL CANAL 434
Jason L. Hornick
10. TUMORS OF THE LIVER, BILIARY TREE, AND GALLBLADDER 477
Linda Ferrell, Sanjay Kakar
11. TUMORS OF THE EXOCRINE PANCREAS 531
David S. Klimstra, Gunter Klöppel
12. TUMORS OF THE URINARY TRACT 559
PART A ■ TUMORS OF THE KIDNEY 559
John N. Eble, David J. Grignon, Robert H. Young
PART B ■ TUMORS OF THE RENAL PELVIS AND URETER 603
John N. Eble, David J. Grignon, Robert H. Young
PART C ■ TUMORS OF THE URINARY BLADDER AND URETHRA 610
John N. Eble, David J. Grignon, Robert H. Young

13. TUMORS OF THE FEMALE GENITAL TRACT 658
PART A ■ OVARY, FALLOPIAN TUBE, AND BROAD AND ROUND LIGAMENTS 658
Charles J. Zaloudek, Karuna Garg
PART B ■ ENDOMETRIAL TUMORS 762
George L. Mutter
PART C ■ TUMORS OF THE PLACENTA AND GESTATIONAL TROPHOBLASTIC DISEASE 784
Mana M. Parast, Yonghee Lee, Christopher P. Crum
PART D ■ MYOMETRIUM 796
Marisa R. Nucci
PART E ■ CERVIX 814
Marisa R. Nucci, Kenneth R. Lee, Christopher P. Crum
PART F ■ VAGINA 838
Marisa R. Nucci
PART G ■ VULVA 850
Marisa R. Nucci
14. TUMORS AND TUMOR-LIKE CONDITIONS OF THE MALE GENITAL TRACT 872
PART A ■ PROSTATE AND SEMINAL VESICLES 872
Jae Y. Ro, Kyu-Rae Kim, Steven S. Shen, Mahul B. Amin, Alberto G. Ayala
PART B ■ TESTICULAR NEOPLASMS 951
Jae Y. Ro, Kyu-Rae Kim, Steven S. Shen, Mahul B. Amin, Alberto G. Ayala
PART C ■ PENIS AND SCROTUM 1010
Jae Y. Ro, Kyu-Rae Kim, Steven S. Shen, Mahul B. Amin, Alberto G. Ayala
15. TUMORS OF THE PERITONEUM 1031
Julie A. Irving, Philip B. Clement

Volume 2

16. TUMORS OF THE BREAST 1057
Ian O. Ellis, Andrew H.S. Lee, Sarah E. Pinder, Emad A. Rakha
17. TUMORS OF THE PITUITARY GLAND 1146
M. Beatriz S. Lopes
18. TUMORS OF THE THYROID AND PARATHYROID GLANDS 1177
PART A ■ THE THYROID GLAND 1177
John K.C. Chan
PART B ■ THE PARATHYROID GLAND 1273
John K.C. Chan
19. TUMORS OF THE ADRENAL GLAND 1294
Ernest E. Lack, Jacqueline Wieneke

- 20. TUMORS OF THE ENDOCRINE PANCREAS** 1326
Gunter Klöppel, Philipp U. Heitz, Aurel Perren
- 21. TUMORS OF THE LYMPHORETICULAR SYSTEM, INCLUDING SPLEEN AND THYMUS** 1343
PART A ■ LYMPH NODE 1343
Scott Rodig, John K.C. Chan
PART B ■ THE SPLEEN 1526
Scott Rodig, John K.C. Chan
PART C ■ THE THYMUS 1558
John K.C. Chan
- 22. TUMORS OF THE HEMATOPOIETIC SYSTEM** 1615
Jeffery L. Kutok
- 23. TUMORS OF THE SKIN** 1680
Daniel J. Santa Cruz, Sarah N. Walsh
- 24. TUMORS OF SOFT TISSUE** 1796
Christopher D.M. Fletcher
- 25. TUMORS OF THE OSTEOARTICULAR SYSTEM** 1871
Carrie Y. Inwards, André M. Oliveira
- 26. TUMORS OF THE CENTRAL NERVOUS SYSTEM** 1933
M. Beatriz S. Lopes, Scott R. VandenBerg
- 27. PERIPHERAL NEUROECTODERMAL TUMORS** 2032
Christopher D.M. Fletcher
- 28. TUMORS OF THE AUTONOMIC NERVOUS SYSTEM, INCLUDING PARAGANGLIA** 2064
Ernest E. Lack, Jacqueline Wieneke
- 29. TUMORS OF THE EYE AND OCULAR ADNEXA** 2086
Robert Folberg
- 30. TUMORS OF THE EAR** 2117
Lester D.R. Thompson
- 31. MOLECULAR GENETIC TECHNIQUES IN DIAGNOSIS AND PROGNOSIS** 2145
Neal I. Lindeman, Jonathan A. Fletcher, Janina A. Longtine

INTRODUCTION

Christopher D.M. Fletcher

In no area of surgical pathology, possibly even in all diagnostic histopathology, does the pathologist play a more important and crucial role than in the diagnosis of tumors. Although patients or laypersons are often entirely ignorant of this role and fondly imagine that their surgeon, other clinician, or oncologist is the true diagnostician—a misapprehension that some of our colleagues do not always dispel!—the reality is that the histology report is the principal determinant of diagnosis, likely clinical course, and therapy in any patient found to have a swelling or mass that proves to be neoplastic.

The need for timely, accurate, and detailed reports has never been greater, especially in our increasingly subspecialized profession and litigious society. This need comes at a time when the fields of tumor pathology and surgical pathology in general are expanding at an unprecedented rate, as reflected in the constant characterization of previously unrecognized tumor types or variants and the advancing delineation and application of new technologies that provide objective aids, not only to diagnosis but also to prognostication and to the understanding of pathogenetic mechanisms. This almost daily expansion in the surgical pathologist's "database" is manifest in the perceived need for ever more numerous journals and textbooks, which of themselves become more and more subspecialized. It is against this background that we have attempted to put together a book dealing solely with the diagnostic histopathology of tumors in all organ systems, employing contributors who are all recognized specialists in their own areas of this field. I use the term "we" to underline the close nature of the collaboration among editor, contributor, and publisher in a project of this scale, but all errors and omissions, as in prior editions, are the sole responsibility of the editor. It should also be admitted that the rate at which surgical pathology is progressing will be reflected in the fact that some small parts of this book will inevitably be outdated or superseded by the time of publication!

The philosophy of this book has been to use the word "tumor" in its traditionally descriptive sense, in other words, to encompass neoplastic and, in some cases, non-neoplastic swellings. In this regard, it is commonly impossible, or at least a source of unresolved argument, to know whether certain lesions should be classified as hamartomatous, hyperplastic, or neoplastic, and, most often, this text has adopted a pragmatically neutral role. It is of interest to note that currently no generally accepted definition of a neoplasm exists, because clonality alone is undoubtedly insufficient in this regard: some processes traditionally regarded as reactive, for example

in lymphoid tissue and synovium, have been shown to be clonal or oligoclonal. The capacity for growth in a transplanted (xenograft) model is perhaps the most convincing criterion but is not readily applicable in a routine setting! Although the focus of this book is inevitably on histomorphology and associated ancillary tests, basic clinical data are also provided for most lesions, because these contribute significantly to accurate classification. The relevance of pathologic assessment in guiding treatment is also emphasized where appropriate. Guidelines to differential diagnosis (with appropriate cross-references where necessary) are described for those tumors that pose a particular or common problem.

This introductory chapter provides an opportunity to put forward, with due modesty, some personal approaches and views regarding the routine practice of diagnostic tumor pathology. The philosophy propounded hereinafter is individual and should not be construed as representing any policy agreed upon by the contributors. Some of the suggestions put forward below undoubtedly are unoriginal but represent simply the "folklore" of surgical pathology, passed down from great teachers in this field. In some quarters today, the passage of such valuable information is regarded as being of little value, and we, as practicing histopathologists, are often encouraged to concentrate on purportedly more objective or "scientific" assessments of diagnosis or prognosis. This is reflected in the remarkable extent to which the content of some large academic meetings worldwide is governed by fashionable, but often transient, techniques, antibodies, genes, or speculations. For as long as human tumors remain more varied, unpredictable, and idiosyncratic than their hosts, in terms of both morphology and behavior, then a clear and unassailable need will exist for good surgical pathology, based principally on careful and experienced light microscopic examination, supported, where appropriate or necessary, by more modern techniques. For the time being at least, such skilled morphologic examination remains the gold standard in anatomic pathology, and it is unlikely to be surpassed in terms of either reliability or cost-effectiveness in the near future. Although it is true that some aspects of diagnostic pathology are subjective to a troubling degree, and although we should all work toward diagnostic reproducibility and objectivity by whichever means are most effective, it is a simple fact (at least in tumor medicine) that surgical pathology has never played a more important and pivotal role than at the present time. This is largely due to the central role of histopathologic parameters in determining therapy (at least for the large majority of tumors) and

hence the wish of clinicians to obtain (and often discuss) detailed pathology reports. The manner in which expertise in surgical pathology is often taken for granted in some academic centers, especially in Europe and the United States, is reprehensible and, if it continues, may lead to the progressive loss of important diagnostic skills, because of erosion of experiential training and realignment of priorities in academic departments. In part this trend reflects an increasing tendency to shorten training time before certification, as well as the importance attached to grant raising by MD-PhDs and PhDs engaged in basic research, one outcome of which has been to widen the gap between much of the research undertaken in academic medical centers and the primary clinical mission of a hospital environment. A clear need exists for increased numbers of true physician scientists, increased funding for clinical and translational research, and greater mutual respect and collaboration between physicians and laboratory scientists. No one is better placed to take advantage of such collaborative opportunities than pathologists.

The guidelines that follow are set out in an order that corresponds, as far as possible, to the events in a surgical pathology laboratory from receipt of a specimen to the issuance of a report.

To diagnose a tumor in the absence of clear and complete clinical data is foolhardy, dangerous, and sometimes impossible. Many of our clinical colleagues often need to be reminded of this fact; even simple information concerning age, sex, or location may be missing on the request form. This may raise compliance issues in addition to the potentially negative impact on patient care. If a specimen arrives in the laboratory without such data, then a medically qualified member of staff should not hesitate to contact the errant clinician or his or her staff; sometimes it may be appropriate to withhold the report until the pathologist is fully apprised of the necessary information. If a history of any previous neoplasm exists, especially at the same anatomic location, then the date of biopsy, diagnosis, and laboratory reference (when available) should be requested and recorded. If ancillary data, such as the radiologic findings or serum chemistry in a bone tumor, are necessary to make a diagnosis, then these should be requested, if not demanded!

Accurate and careful macroscopic description of a tumor specimen, particularly the definitive resection, is vital to diagnosis, prognosis, and retrospective data analysis for pathologic or clinical studies. The first occasion on which a resection specimen is examined in the pathology laboratory is usually the one and only time at which tumor size, weight, approximate extent of necrosis, and distance to resection margins can be gauged properly; once the specimen has been dissected, cut up, fixed, and otherwise distorted, then such valuable parameters often cannot be assessed. Similarly, features such as the type of margin (encapsulated, circumscribed, or infiltrative), the presence of satellite nodules, the presence (or involvement) of lymph nodes, and the extent of spread or invasion of adjacent structures are often best determined at the time of specimen dissection. The macroscopic description of the tumor in the final report should be sufficiently detailed to enable any other pathologist to

conjure a clear mental image of the neoplasm. If this is done well, then often, in combination with the clinical data, it is possible to have a good idea of the final diagnosis, even before seeing the slides, especially in the more common tumor types. The other important role of good macroscopic examination is to ensure that a tumor is adequately sampled. The type or extent of sampling varies according to the size and anatomic location of the neoplasm, but, as a general rule of thumb, all lesions of appreciable size (perhaps >2 cm) should be sliced serially, and all areas showing a differing appearance should be examined histologically. In the appropriate organ systems, care should be taken to obtain blocks at the most likely site of muscular, serosal, or capsular invasion, as determined by naked-eye examination. Given the currently prevailing fashion for inking specimen margins, I would like to make a plea in this regard—think before you ink! The indiscriminate inking of specimens, almost irrespective of type, has led in some contexts to the time-wasting and often irrelevant examination of margins in lesions that either have no potential to recur or else have been so obviously marginally or incompletely excised that the positive (or at least oncologically inadequate) margins can be recorded grossly. In some cases, lesions (or biopsies) that are so small that they are embedded and sectioned in their entirety in one block are still inked, yet it is hardly a challenge to assess the margins (without inking) in such cases. This trend in specimen handling is almost anti-intellectual, often obliterates the benefit of examining a specimen in a thoughtful manner, and taints the validity of inking, which can be invaluable in an appropriate context.

Turning now to histologic evaluation, clearly this is a complex, often organ-specific process, the details of which are described in the separate chapters of this book. However, one or two pertinent generalizations can be made. Generalizations admittedly are dangerous and stand only to be shot down by exceptions to each rule; however, I believe that they provide useful guidelines. In any patient with a previous primary (or recurrent) neoplasm, the slides should always be reviewed. This serves four main purposes: (1) it provides a simple but useful form of audit; (2) it enables comment to be made as to whether a tumor has advanced (or sometimes decreased) in histologic grade, thereby possibly influencing clinical outcome; (3) it is the only way of determining with certainty if a patient has developed two separate primary neoplasms, whether of the same or different types; and (4) sometimes such review provides a vital clue to diagnosis because recurrent or metastatic neoplasms, especially of mesenchymal type, show a remarkable capacity to alter their phenotype or to lose evidence of specific differentiation. What appears to be a weird or undiagnosable neoplasm, on occasion, can suddenly become a simple case when the previous histology is reviewed! In this regard, the principle of Occam's razor should be remembered: a patient is always more likely to have a single primary neoplasm with an odd pattern of recurrence than to have two separate primaries.

A second generalization, which, although possibly a philosophic point, I personally regard to be of paramount importance, is that strict histologic criteria should be

used for all tumor diagnoses. With rare exceptions, usually relating to specialist expertise based on experience, it is not acceptable to make an arbitrary diagnosis founded on personal whim. If a colleague or trainee asks how a diagnosis was reached, one should be able to enumerate reasons or criteria, be they positive or negative findings; hopefully, the days of saying "It is what it is because I say it is" are gone! The merits of this practice are that (1) uniformity in diagnosis is increased, thereby facilitating treatment decisions; (2) when analyzing published data or initiating new studies (whether clinical, pathologic, genetic or genomic), one can ideally compare like with like—a vital step toward understanding tumor morphology and behavior, especially if large multicenter studies are required; and (3) the provision of clear diagnostic criteria is the only reliable means by which trainee pathologists can be taught. In this regard we need to introduce morphologic objectivity whenever possible, even though surgical pathology, by necessity, remains a subjective art, at least in part.

The third, hopefully well-known, generalization applicable to light microscopic examination of tumors using hematoxylin and eosin (H&E)-stained sections is that, in most (but not all!) cases, low-power appearances often provide the best guide to the separation of benign from malignant lesions. Features such as the preservation of normal (often lobular) architecture, lesional symmetry, and the general impression of overall cellularity and nuclear atypia are exceedingly helpful in this distinction. Conversely, if one rushes straight to the high-power lenses, it is remarkably easy to find (and be misled by) cells with atypical or worrisome features in a very wide range of tumors or pseudoneoplastic lesions. Good examples of this phenomenon are the bizarre, often multinucleate, stromal cells found in the submucosa or lamina propria of reactive, often polypoid lesions at almost any mucosal or cutaneous location and the densely hyperchromatic, irregular, degenerative ("ancient") nuclei encountered in a variety of soft tissue neoplasms. Similarly, the presence of single, or very rare, abnormal mitotic figures need not equate with malignancy: I will always remember being shown such a mitosis in an otherwise normal proliferative endometrium during my first year in pathology!

With regard to the application of more modern techniques to diagnostic practice, this is mentioned (where relevant) in each chapter and is discussed in greater detail in Chapter 31. Immunohistochemistry, which now is more than 30 years old and therefore no longer regarded as modern by the arbiters of fashion, is indeed very useful but must always be interpreted in context. A seemingly aberrant result, especially if this is a negative result, should never be allowed to overrule an obvious morphologic diagnosis. Conversely, it should be recognized that the current fashion for enthusiastic antigen retrieval often leads to many confusing false-positive results—for example, in recent years, this has been a notable problem in the use of CD117 positivity to accurately confirm a diagnosis of gastrointestinal stromal tumor. Quality control is vital if immunohistochemistry is to have any worthwhile role, and often this requires that any given laboratory should have a "minimum throughput," albeit

this required level of work activity is poorly defined. Laboratories that perform a large number of immunostains on a daily basis and do not change the staff around unnecessarily almost invariably produce more consistent and better-quality results than their smaller, intermittently utilized counterparts. The value of using large antibody panels or complex algorithms for immunodiagnosis is somewhat controversial, but, in these days of cost-effectiveness, it is my view that the choice of immunostains, where necessary, should be governed (and limited) by a carefully assessed differential diagnosis, based on H&E morphology, through which specific questions need to be answered. The broader and more mindless a panel of antibodies becomes, the greater is the likelihood of obtaining inexplicable, misleading, or aberrant results. Equally, if reliance is placed on an algorithm (especially one generated by a laboratory other than one's own), then a single aberrant or false-positive (or negative) result can lead to an irrational diagnosis, as well as a lengthy and costly trail of immunostains. A separate point of contemporary importance is the increasing trend of using immunohistochemistry or molecular testing for identification of potential therapeutic targets (e.g., c-kit or various growth factor receptors). Meaningful target identification and validation are an important and expanding activity in pathology, but pathologists must not allow themselves to be bullied into undertaking such testing unless the protein or gene in question has been proved to have biologic relevance (usually through activation or mutation) in the given tumor type and unless well-validated, reliable, and reproducible antibodies are available for this purpose.

With regard to many of the more recent molecular genetic techniques, some of which undoubtedly have proved (and will continue to prove) to be valuable in tumor pathology, two points should be borne in mind. First, the published results concerning a pattern of gene expression or karyotypic abnormality in a given tumor type are only as meaningful (or as valid) as the corresponding morphologic diagnoses. If the diagnoses on which these results are based happen to be inconsistent or even wrong, then the conclusions made are often rendered worthless. Therefore collaboration and mutual respect between anatomic pathologists and basic scientists are absolute prerequisites for continued progress in this setting. As expression profiling and sequencing technologies begin to allow rapid and detailed molecular profiling of large numbers of tumors, such professional interactions will be crucial in validating such data and in extracting maximal clinical value from this new information. In this regard, it is important to note that the majority of genomic profiling studies in recent years, trumpeting new-found diagnostic or prognostic accuracy, have failed (with a few notable exceptions) to improve on the daily achievements of routine light microscopic techniques. This may in part reflect the fact that many such studies have not included expert pathologists in the research team. Thus the second key point, despite initial optimism, is that many of the molecular and genetic parameters assessed in recent years, with important exceptions (e.g., N-myc amplification in neuroblastoma, cytogenetic and molecular characterization of many leukemias and

sarcomas, detection of minimal residual disease in hematolymphoid neoplasms, and the detection of therapeutically important mutations in certain tumor types, for example non-small cell lung cancer and melanoma), have not improved on careful (or expert) light microscopic examination for diagnosis and prognosis. The latter therefore remains the gold standard against which all new technology needs to be assessed; claims that newer modalities provide greater objectivity should be weighed not only against financial cost and problems of reproducibility in nonspecialized laboratories, but also against the frequency with which such claims seem to be proved wrong, as witness previous descriptions of so-called cancer-specific antigens or mutations, the short-lived misapprehension that expression of p53 was a reliable marker of the malignant phenotype, or the persistently unproved (and unvalidated) tests, often aggressively marketed, that claim to accurately predict primary site or response to chemotherapy.

Once a diagnosis has been reached, then a report must be formulated, guidelines for which are well beyond the remit of a book of this type. However, it is important to ensure that any report provides as much useful information to the clinician as possible, and, in this context, increasingly good reasons exist to use synoptic (or template) reporting formats, especially for common tumor types. In this way, key elements of information are not forgotten and the clinician's ability to interpret a report is maximized. Not only does this mean the inclusion of clear statements regarding tumor type, grade, or stage (where applicable) and status of resection margins, but the report offers a unique opportunity to provide general data concerning clinical features, likely behavior, and ideal management, supported by references to the published literature where appropriate. The transmission of such information may be appropriate only in the case of uncommon or unusual neoplasms, and the extent to which a surgical pathologist will feel able or comfortable to offer advice on therapy will depend greatly on local circumstances and the tolerance or insight of clinical colleagues. In my view, however, surgical pathologists should never forget that they are providing a clinical, often subjective, opinion quite different from the type of report required of some other specialties in pathology, and in this circumstance we should not shy away from offering whatever expertise or background data are available to us. It is an extraordinary but undoubted fact that the key articles describing clinical features and therapeutic outcome in many tumor types are published, at least initially, in pathology, rather than clinical, journals. Often, therefore, surgical pathologists are more likely to have received (and hopefully read!) the latest published studies on the general aspects of a given neoplasm than their clinical colleague. However, any tendency to try and achieve "one-upmanship" in this relationship should be carefully curbed until such time as pathologists can feel sure that they have also scanned the relevant clinical literature!

To conclude this introductory chapter, I would like to offer some simple truisms applicable to diagnostic tumor pathology that notably have not changed in the past 20 years. Many of these are self-evident and most likely are

widely known; the frequency with which they are forgotten is therefore all the more remarkable and regrettable:

1. By virtue of simple statistical probability, common things remain common; therefore do not be tempted into an esoteric (or exciting!) diagnosis until you have confidently excluded a more probable diagnosis. A good example that typifies this pitfall is the characterization of spindle-celled malignant neoplasms arising in breast or epithelial-lined viscera, such as the upper aerodigestive tract or urinary bladder; sarcomatoid (or spindle cell) carcinomas are a far more likely prospect than some unusual sarcoma or so-called carcinosarcoma.
2. Pathologists should never be afraid to request a larger (or repeat) biopsy if they are having difficulty in coming to a firm diagnosis before definitive therapy. It is a matter of fact that some tumor biopsies are inadequate or unrepresentative. In fact the increasing trend for our clinical and radiologic colleagues to provide smaller and smaller biopsies (in the names of cost-effectiveness and convenient patient care) is not only limiting our ability to make definitive diagnoses but also diminishing the opportunity to provide valuable prognostic information. This tide needs to be stemmed, or at least challenged and first validated, especially because the use of preoperative neoadjuvant therapy is also increasing and often renders the ultimate resection specimen relatively useless for diagnostic or prognostic purposes. Painful hours, or even days, of indecision followed by an inconclusive or, worse, inappropriately confident report are far better avoided by a clear request for more tissue. On occasion this undoubtedly prevents the institution of inappropriate therapy. Any attempt to hedge (or spread) one's bets in a diagnostic report should be avoided whenever possible.
3. Pathologists should never be afraid to admit that they cannot diagnose or classify a given neoplasm. No pathologist on this planet does not sometimes benefit from a second opinion, however intermittent this need may be. Pathologists who believe that they never need a second or specialist opinion are dangerous. Increasingly this becomes true in anatomic pathology, which is ever more subspecialized and in which the days of the true generalist are numbered. Conversely, a subset of human tumors will always remain that defy rational classification by anyone. In this context clues may exist (but not always) to the likely clinical behavior of such a neoplasm, even if the line of differentiation is obscure, but such clues should be interpreted only tentatively; the reality is that if one cannot categorize a neoplasm reliably on morphologic grounds, then any attempt at prognostication is inevitably unreliable and only amounts to more or less sophisticated guesswork!
4. The (possibly obvious) corollary of the previous point is that pathologists can diagnose only what they have seen, read, or heard about previously. This sets clear limitations on the interpretative skills of any pathologist and underlines the need to

keep abreast of recent continued developments, by either regular attendance at postgraduate meetings or the routine perusal of major journals in our specialty. Those (increasingly few) who insist on regarding the recognition or recategorization of diagnostic entities as worthless “splitting” do so at their peril; those who attempt to force all tumor diagnoses into categories with which they are already familiar do likewise.

5. A further point that is related, at least peripherally, to the “don’t know” situation, is that a pathologist (or, for that matter, any other practicing physician) should never be afraid to admit a mistake. Every pathologist has made at least an occasional error, however trivial or clinically insignificant, and anyone who suggests otherwise is probably deluded. Our specialty is an interpretative skill or art, not a black-or-white measurement, and therefore human error is unfortunately inevitable. Far more trouble can be generated by concealment or dishonesty in this regard than by admitting a suboptimal diagnosis.
6. Prognostication in cancer management, especially among clinical oncologists, is often believed to rely largely on tumor grade and stage, both of which the pathologist may be instrumental in assessing. Some clinicians believe that such parameters (particularly grade) can be determined in the absence of a specific diagnosis. In the light of the foregoing discussion, this is clearly nonsensical, and it is up to surgical pathologists to resist this trend. In very many organ systems, the principal determinant of likely outcome is accurate histologic typing, and the importance of an unequivocal diagnosis should never be underestimated. Equally in some types of cancer, substratification by grade is meaningless because a given tumor type may invariably be biologically low grade (e.g., infantile fibrosarcoma) or high grade (e.g., pleural malignant mesothelioma), irrespective of histologic appearances. Therefore it is important to recognize that grading (and often also staging) systems need to be tailored, in many cases, to the individual tumor type, and this is one circumstance in which generalizations can undoubtedly be dangerous. In parallel, we need to take care that the rush to incorporate mutational analysis as a component of prognosis or treatment selection (as, for example, in gastrointestinal stromal tumors and non-small cell lung carcinomas) does not bypass careful validation studies, remains confined to the tumor types for which such validation has been achieved, and has demonstrable clinical impact. For the relative lack of significant

therapeutic advances in some tumor types to hide behind the use of ever more sophisticated (and expensive) diagnostic or prognostic technologies is not a desirable outcome.

This discussion also begs the question of what constitutes a high-grade neoplasm; there are no easy or clear answers to this question, but the following examples provide food for thought and should prompt careful appraisal of the manner in which we, as doctors, assess malignant neoplasms. Consider the following three patients: the first is a 60-year-old man with an inoperable small cell carcinoma of bronchus; we know that his tumor is likely to disseminate rapidly, despite chemotherapy, and his prospects of surviving more than 12 months are slim. The second is a 25-year-old woman with localized alveolar soft-part sarcoma of the thigh; we know that her 5-year survival probability is 60% to 70%, and, with this information, she may well form a stable relationship and start a family—but we also know that her chances of surviving beyond the age of 45 years are no more than 15%, because most patients with this type of tumor eventually have distant metastases. The third is a 45-year-old with a grade 2 astrocytoma in the frontal lobe; we know that the risk of extracranial spread (metastasis) is very small but that the chances of postsurgical recurrence are high; we also know that such recurrences are likely to be progressively fatal over a 5- to 10-year period. I believe that all three patients would be justified in claiming that they had a biologically high-grade neoplasm, yet the perception of the physician, pathologist, or scientist in each case would undoubtedly be different, particularly with regard to the inherent biology of these tumors. This variability underlines the need to treat tumors on the basis of biologic, rather than histologic, grade, at least in those circumstances in which our therapeutic options allow any flexibility.

7. The last, and perhaps most straightforward, truism is that histology reports, whether on specimens from one’s own hospital or from a patient thousands of miles away, should be as prompt as is feasible and safe. The surgical pathology report is not simply a matter of record or a means of rubber-stamping a clinical suspicion; in the context of tumor pathology, almost always it is the diagnostic arbiter and one of the major determinants of therapy. It impinges enormously on patients, even if they are commonly unaware of this fact. Any pathologist who fails to recognize or shoulder this responsibility might best be advised to consider alternative employment!

TUMORS OF THE HEART AND PERICARDIUM

Henry D. Tazelaar • Joseph J. Maleszewski

CHAPTER OUTLINE

General Clinical Features 6
Benign Tumors of the Heart and
Pericardium 7

Malignant Tumors of the Heart and
Pericardium 32

All of the entities presented here form tumors. Among the benign tumors, some are correctly classified as neoplasms, some as pseudoneoplasms, some as hamartomas or heterotopias, and some as processes somewhere in between. No firm distinctions are drawn in this discussion as the emphasis is on accurate diagnosis, not histogenesis. It is important to note that, although the tumors discussed in this chapter represent primary cardiac tumors, by far the most commonly encountered cardiac tumors are metastatic lesions from other primary sites (most commonly lung, breast, and cutaneous melanoma).

More than 90% of primary cardiac tumors are benign, with the majority in adults being myxomas. In infants and children the most common primary tumor of the heart is the rhabdomyoma. Malignant cardiac and pericardial tumors, like malignant tumors elsewhere in the body, have the ability to invade and metastasize. Benign cardiac tumors as well, however, can have clinically malignant consequences given the frequency of endocardial or conduction system involvement. Table 2-1 lists the most common cardiac tumors, including true neoplasms, hamartomas, and pseudoneoplasms.

GENERAL CLINICAL FEATURES

The clinical manifestations of cardiac tumors are often nonspecific. Indeed, many other diseases may be mimicked. The clinical presentation is usually subdivided under three major headings: (1) systemic, (2) embolic, and (3) cardiac. Clinical features reported to occur with each tumor will not be mentioned in the discussion of that tumor, unless specific to that tumor for some reason.

Systemic Manifestations

The systemic manifestations of tumors of the heart are manifold and include findings such as fever, cachexia, and malaise. Abnormal laboratory findings that may develop include an elevated erythrocyte sedimentation rate,

hypergammaglobulinemia, thrombocytosis or thrombocytopenia, polycythemia, leukocytosis, and/or anemia. The mechanisms that underlie these systemic manifestations are not as yet fully understood, but it is likely that they relate to release of cytokines as part of an inflammatory reaction.¹⁻³

Many cardiac tumors are also associated with clinical systemic syndromes and genetic diseases. A summary is found in Table 2-2.

Embolic Manifestations

These events can be due to embolization either of fragments of the tumor itself or of thrombi aggregated on the surface of the tumor. Embolization of tumor fragments can occur only when the tumor itself shows intracavitary extension. Thromboemboli, on the other hand, can also occur with intramural tumors, which compromise the function of the heart leading to intracavitary thrombosis.

The pathologist may be the first to suspect the presence of a cardiac tumor on the basis of examination of a peripheral embolus. In fact sudden occlusion of a peripheral artery in an otherwise healthy person should always raise the possibility of a cardiac tumor. An embolectomy specimen, therefore, should be examined most carefully for the presence of tumor fragments. However, even when only recent thrombotic material is found, it is wise to mention the possibility of a coexistent cardiac tumor. Moreover, multiple systemic emboli may mimic systemic vasculitis or infective endocarditis, particularly when associated with systemic manifestations. Primary tumors of the right heart chambers may cause pulmonary emboli, which may be indistinguishable from those occurring as a result of venous thrombosis.

Cardiac Manifestations

The cardiac events that can develop as a result of cardiac tumors are largely determined by the location and size of